Somatostatin and somatostatin analogues: Diagnostic and therapeutic uses

Current Opinion in Oncology

Volumn 14, Issue 1, 2002, Pages 53-57

  De Herder, Wouter W ^a   Lamberts, Steven W J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; OCTAPEPTIDE; OCTREOTIDE; PENTETATE INDIUM IN 111; PENTETREOTIDE IN 111; RECEPTOR SUBTYPE; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE;

ADULT; BINDING AFFINITY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG RECEPTOR BINDING; FEMALE; HUMAN; INJECTION; ISOTOPE LABELING; METASTASIS; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; REVIEW; SCINTIGRAPHY; SIDE EFFECT;

ANTINEOPLASTIC AGENTS, HORMONAL; FORECASTING; HUMANS; NEUROENDOCRINE TUMORS; OCTREOTIDE; PEPTIDES, CYCLIC; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 0036148991     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200201000-00010     Document Type: Review

References (32)

1. Octreotide
2. Somatostatin receptors
3. Somatostatin and its receptor family
4. Antiproliferative effect of somatostatin and analogs
5. Somatostatin analogue treatment of neuroendocrine tumors
6. Peptide receptors in gut endocrine tumours
7. Established clinical use of octreotide and lanreotide in oncology
8. Somatostatin analogs for cancer treatment and diagnosis: An overview
9. Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analogue
10. Treatment of neuroendocrine GEP tumours with somatostatin analogues: A review
11. Carcinoid tumour
12. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: A prospective study in 39 patients
13. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms
14. Octreotide as primary therapy for acromegaly
15. Slow-release lanreotide in the treatment of acromegaly: A study in 66 patients
16. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly
17. Thyrotropin-secreting pituitary tumors
18. A prospective multicenter trial of octreotide in 24 patients with visual defects caused by nonfunctioning and gonadotropin-secreting pituitary adenomas
19. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors
20. 3]-octreotide: The Rotterdam experience with more than 1000 patients
21. Peptide receptor imaging and therapy
22. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy
23. 1]octreotide scintigraphy in patients with carcinoid tumours: The predictive value for somatostatin analogue treatment
24. Receptor imaging in the diagnosis and treatment of pituitary tumors
25. Imaging of pituitary tumours
26. Intraoperative localization of gut endocrine tumors with radiolabeled somatostatin analogs and a gamma-detecting probe
27. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy
28. OctreoTher: Ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy
29. 3] octreotate for somatostatin receptor-targeted radionuclide therapy
30. Somatostatin analogs in oncology: A look to the future
31. 2) gene expression and administration of cytotoxic somatostatin analog AN-238
32. Karnofsky memorial lecture: An odyssey in the land of small tumors